The Critical Importance of the Master Cell Bank Our last post, ‘The Product is the Process – The Master Cell Bank 1‘, unequivocally presented the genetically-engineered cells that produce ‘protein-based drugs’, as the foundation of biopharmaceutical production. So fundamental are these cell lines in fact, that if a manufacturer were to lose them to contamination for example, further production would be impossible. Additionally, restoration … Read More
The Product is the Process – The Master Cell Bank 1
Introduction The phrase ‘The Product is the Process‘, encapsulates the unique relationship between the production process and the characteristics of the resultant biopharmaceutical product. This inextricable relationship between the process and the product is not seen with the production of conventional chemically-derived drugs. With conventional drugs, it is not uncommon for the sequence of production steps to be altered with little effect on the final … Read More
Biopharmaceutical Manufacturing – Part 2
Continuing from our last post, ‘Biopharmaceutical Manufacturing 1‘, this current post, ‘Biopharmaceutical Manufacturing 2‘, elaborates upon the steps in biopharmaceutical manufacture after insertion of the ‘gene of interest‘ into the ‘Expression Vector‘. We therefore begin this post at Step 6 of our Manufacturing Process Flow in which the ‘Vector‘ transports our gene of interest into the host cell. This is presented in even greater detail … Read More
Biopharmaceutical Manufacturing – Part 1
Introduction As noted in earlier posts, because biopharmaceutical manufacturing is dependent upon production within living cells, it is more complex and prone to variability than production of conventional ‘small-molecule‘ / ‘chemical‘ pharmaceuticals. The number of steps involved as well as the complexity of each step, present many opportunities for variability to enter the production process. In fact, minimizing this variability is perhaps the greatest … Read More